Teva Pharmaceutical Industries Limited (TEVA) Position Increased by Court Place Advisors LLC

Court Place Advisors LLC raised its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 26.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,767 shares of the company’s stock after buying an additional 2,435 shares during the period. Court Place Advisors LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $391,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in TEVA. Cribstone Capital Management LLC raised its position in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares in the last quarter. FNY Managed Accounts LLC acquired a new position in Teva Pharmaceutical Industries Limited during the first quarter valued at about $123,000. Sterling Investment Advisors Ltd. raised its position in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares in the last quarter. Finally, Financial Architects Inc raised its position in Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares in the last quarter. 56.26% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Limited (TEVA) traded up 0.65% during trading on Friday, hitting $32.64. 3,251,371 shares of the stock traded hands. The firm has a 50-day moving average price of $31.34 and a 200 day moving average price of $32.48. Teva Pharmaceutical Industries Limited has a 12 month low of $27.59 and a 12 month high of $55.79. The firm has a market cap of $33.16 billion, a PE ratio of 418.46 and a beta of 0.47.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, May 11th. The company reported $1.06 EPS for the quarter, meeting the Zacks’ consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a net margin of 1.49% and a return on equity of 16.38%. The company had revenue of $5.63 billion during the quarter, compared to analysts’ expectations of $5.69 billion. During the same quarter in the prior year, the company posted $1.20 earnings per share. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 17.0% compared to the same quarter last year. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.75 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/07/23/teva-pharmaceutical-industries-limited-teva-position-increased-by-court-place-advisors-llc.html.

TEVA has been the subject of several research reports. Oppenheimer Holdings, Inc. set a $43.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a report on Thursday, April 6th. Cantor Fitzgerald set a $31.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a report on Thursday, June 22nd. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Credit Suisse Group reissued a “buy” rating and set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, May 17th. Finally, BidaskClub raised Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 13th. Sixteen research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and an average target price of $42.78.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit